Heloisa Soares
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
Radioligand therapy (RLT) offers the ability to deliver radiation to specific cells based on the presence of certain targets. RLT with [177Lu]Lu-DOTATATE was approved in 2018 by the US Food and Drug Administration (FDA) for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As RLT has become integrated into clinical practice, understanding the presence of and management strategies associated with acute, subacute, or delayed toxicities is essential to optimize patient outcomes. In this review article, we consider the risk factors for complications and any preventative strategies that may be employed. We present an overview of the toxicities that could occur during or soon after RLT infusion and discuss recommended management strategies, both from the literature and from experience in the clinical administration of RLT for patients with GEP-NETs. We highlight the importance of robust procedures for handling emergency situations and the potential for radioactive contamination from patients’ bodily fluids. Furthermore, the potential for delayed toxicities is also considered. In addition to toxicities and management, we also review the practical radiation safety precautions that are important both during and following RLT treatment.
Year:
2026
Year:
2026
Biliary tract cancers (BTC) are a rare and aggressive consortium of malignancies, consisting of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma. While most patients present with metastatic disease, a minority of patients with BTC are eligible for curative surgical resection at the time of presentation. However, these patients have poor 5-year overall survival rates and high rates of recurrence, necessitating the improvement of the neoadjuvant and adjuvant treatment of BTC. In this review, we assess the neoadjuvant and adjuvant clinical trials for the treatment of BTC and discuss the challenges and limitations of clinical trials, as well as future directions for the treatment of BTC.
Year:
2025
Supplementary Figure S3: Immune repertoire of DLL3-high versus –low NENs across anatomic sites. Stacked radar plots comparing the imputed cell fractions of immune cells between DLL3-high and -low samples in (A) lung NECs, (B) lung NETs, (C) prostate NENs, and (D) bladder NENs. *q
Year:
2025
Supplementary Figure S2: Correlations between expression of DLL3, ASCL1, and NEUROD1 across select NEN sites. Scatterplots displaying the expression of DLL3 vs ASCL1 (top) and DLL3 vs NEUROD1 (bottom) across NEN sites. Expression is depicted as log(TPM + 0.001). Spearman correlations and corresponding p-values are shown for each site.
Year:
2025
Supplementary Figure S1: UMAP view of NEN samples across diverse anatomic sites. Samples were unbiasedly clustered based off the top 1,000 variably expressed genes across samples and annotated using (A) DLL3 expression level and (B) anatomic site of origin.
Year:
2025
Supplementary Figure S4: Genetic dependencies in neuroendocrine cancer cell lines. Scatterplot displaying gene depletion effects in NEN lines represented in DepMap. Data points represent the mean gene depletion effect of each gene target. Highlighted genes represent potential dependencies (gene effect
Year:
2025
PURPOSE The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, necessitating the identification of resistance mechanisms for effective treatment strategies. Previous studies suggest that targeting the aberrant expression of mTOR regulators p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT) sensitizes pNENs to everolimus. In this study, we queried a large real-world data set of pNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes associated with aberrant PAK4 and NAMPT expression. METHODS Two-hundred and ninety-four pNEN cases were analyzed using next-generation sequencing and whole-exome/whole-transcriptome sequencing. We stratified patients into clusters on the basis of median cutoff. RESULTS High expression of genes activated in response to mTOR activation was found in NAMPT-high and PAK4-high groups. Enrichment of PI3K/AKT/mTOR and glycolysis pathways was observed in these tumors. Higher mutation rates in multiple endocrine neoplasia type 1, alpha thalassemia/mental retardation syndrome X-linked, TSC2, SETD2, and CCNE1 were observed in high NAMPT and PAK4 clusters. Immune analysis revealed enrichment in inflammatory response pathways, IL2/STAT5 signaling, and immune checkpoint genes. Increased neutrophils, natural killer cells, and macrophages were found in PAK4-high/NAMPT-high tumors. Analysis of real-world patient data revealed that high PAK4 ( P = .0428) or NAMPT ( P = .0002) expression individually correlated with lower overall survival in all neuroendocrine neoplasms (NEN) cohorts, while the combined high expression of both was associated with the worst outcomes ( P = .0002). Similar trends were observed in pancreatic NEN cohorts. CONCLUSION Our study demonstrates that PAK4-high/NAMPT-high pNENs are associated with distinct molecular and immune profiles. Further investigation is warranted to determine if dual PAK4 and NAMPT blockade enhances the efficacy of immunotherapeutics.
Year:
2025
Supplementary Figure S1: UMAP view of NEN samples across diverse anatomic sites. Samples were unbiasedly clustered based off the top 1,000 variably expressed genes across samples and annotated using (A) DLL3 expression level and (B) anatomic site of origin.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (25)
Matthew H Bailey
Assistant Professor
Brigham Young University
John Lozada
University of Rochester Medical Center
Benedito A. Carneiro
-
Akhilesh Kumar
Faculty, Assistant Professor
University of Minnesota
Misako Nagasaka
University of California Irvine School of Medicine
Emil Lou
University of Minnesota
Bassel El-Rayes
Deputy Director
University of California, San Diego
SANJAY GOEL
Rutgers University
Bassel Nazha
Emory University School of Medicine
Hyun Kim
Associate Professor
City Of Hope National Medical Center
Justin Hwang
Associate Professor
University of Minnesota
Elisabeth I. Heath
Wayne State University School of Medicine
Bhavana Konda
-
Vaia Florou
Associate Professor
Huntsman Cancer Institute
Ignacio Garrido-Laguna
University of Utah School of Medicine
Rachna Shroff
University of Arizona
Frank Cichocki
Assistant Professor
University of Minnesota
Thorvardur Halfdanarson
Professor of Oncology
Mayo Clinic
Emily Egusa
University of California, San Francisco
Emmanuel S. Antonarakis
-
Mohd Khushman
Professor
Washington University in St. Louis
Jeffrey S Miller
University of Minnesota System
Kathleen Storey
Assistant Professor
University of Minnesota
Nicholas Zorko
Assistant Professor
University of Minnesota
Boris Pasche
Chair
Karmanos Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.